Logo
x

Search

Subscribe Now

Boehringer Ingelheim

Boehringer Ingelheim Join Forces with Circle Pharma to Develop a Novel Precision Cancer Treatment

Boehringer Ingelheim Join Forces with Circle Pharma to Develop a Novel Precision Cancer Treatment

  • October 10, 2024
Boehringer Ingelheim Reports the P-III (FIBRONEER-IPF) Trial Data of Nerandomilast to Treat Idiopathic Pulmonary Fibrosis (IPF)

Boehringer Ingelheim Reports the P-III (FIBRONEER-IPF) Trial Data of Nerandomilast to Treat Idiopathic Pulmonary Fibrosis (IPF)

  • September 20, 2024
Boehringer Ingelheim Reports the Acquisition of Saiba Animal Health, Strengthening its R&D Portfolio Focusing on Animal Health

Boehringer Ingelheim Reports the Acquisition of Saiba Animal Health, Strengthening its R&D Portfolio Focusing on Animal Health

  • September 3, 2024
Boehringer Ingelheim Reports the Acquisition of Nerio Therapeutics for $1.3B

Boehringer Ingelheim Reports the Acquisition of Nerio Therapeutics for $1.3B

  • July 31, 2024
Boehringer Ingelheim Reports Additional Data from the P-II Study of Survodutide to Treat Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Boehringer Ingelheim Reports Additional Data from the P-II Study of Survodutide to Treat Metabolic Dysfunction-Associated Steatohe...

  • June 7, 2024
Boehringer Ingelheim and OSE Immunotherapeutics Expand Partnership to Develop Therapies for Cancer and Cardio-Renal-Metabolic (CRM) Diseases

Boehringer Ingelheim and OSE Immunotherapeutics Expand Partnership to Develop Therapies for Cancer and Cardio-Renal-Metabolic (CRM...

  • May 22, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.